nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—Venous thrombosis—Carboplatin—bone cancer	0.0807	0.0936	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Carboplatin—bone cancer	0.0701	0.0813	CcSEcCtD
Dihydroxyaluminium—Extravasation—Carboplatin—bone cancer	0.05	0.0579	CcSEcCtD
Dihydroxyaluminium—Diuresis—Cisplatin—bone cancer	0.0412	0.0478	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Cisplatin—bone cancer	0.0402	0.0466	CcSEcCtD
Dihydroxyaluminium—Blindness transient—Methotrexate—bone cancer	0.0384	0.0445	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Carboplatin—bone cancer	0.0367	0.0426	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Cisplatin—bone cancer	0.0237	0.0275	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Cisplatin—bone cancer	0.0206	0.0238	CcSEcCtD
Dihydroxyaluminium—VDAC2—connective tissue—bone cancer	0.02	0.145	CbGeAlD
Dihydroxyaluminium—VDAC1—connective tissue—bone cancer	0.0158	0.115	CbGeAlD
Dihydroxyaluminium—Infection—Carboplatin—bone cancer	0.0154	0.0179	CcSEcCtD
Dihydroxyaluminium—Extravasation—Cisplatin—bone cancer	0.0147	0.017	CcSEcCtD
Dihydroxyaluminium—TNNC1—connective tissue—bone cancer	0.0136	0.0987	CbGeAlD
Dihydroxyaluminium—Pain—Carboplatin—bone cancer	0.0133	0.0154	CcSEcCtD
Dihydroxyaluminium—VDAC2—spinal cord—bone cancer	0.0133	0.0964	CbGeAlD
Dihydroxyaluminium—Body temperature increased—Carboplatin—bone cancer	0.0123	0.0143	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Epirubicin—bone cancer	0.0122	0.0141	CcSEcCtD
Dihydroxyaluminium—VDAC3—tendon—bone cancer	0.0115	0.0832	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—bone cancer	0.0113	0.013	CcSEcCtD
Dihydroxyaluminium—VDAC3—bone marrow—bone cancer	0.0111	0.0806	CbGeAlD
Dihydroxyaluminium—VDAC3—spinal cord—bone cancer	0.011	0.0803	CbGeAlD
Dihydroxyaluminium—Encephalopathy—Methotrexate—bone cancer	0.0109	0.0127	CcSEcCtD
Dihydroxyaluminium—VDAC1—tendon—bone cancer	0.0109	0.0792	CbGeAlD
Dihydroxyaluminium—Phlebitis—Cisplatin—bone cancer	0.0108	0.0125	CcSEcCtD
Dihydroxyaluminium—Polyuria—Cisplatin—bone cancer	0.0106	0.0123	CcSEcCtD
Dihydroxyaluminium—VDAC1—bone marrow—bone cancer	0.0106	0.0767	CbGeAlD
Dihydroxyaluminium—VDAC1—spinal cord—bone cancer	0.0105	0.0764	CbGeAlD
Dihydroxyaluminium—Lung disorder—Methotrexate—bone cancer	0.00991	0.0115	CcSEcCtD
Dihydroxyaluminium—TNNC1—tendon—bone cancer	0.00934	0.0679	CbGeAlD
Dihydroxyaluminium—Hyponatraemia—Cisplatin—bone cancer	0.00932	0.0108	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Epirubicin—bone cancer	0.00928	0.0108	CcSEcCtD
Dihydroxyaluminium—Dehydration—Cisplatin—bone cancer	0.00863	0.01	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—bone cancer	0.00858	0.00995	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—bone cancer	0.00804	0.00932	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—bone cancer	0.00752	0.00872	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—bone cancer	0.00747	0.00866	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—bone cancer	0.00696	0.00807	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—bone cancer	0.00691	0.00802	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—bone cancer	0.00641	0.00743	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—bone cancer	0.00638	0.00739	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Cisplatin—bone cancer	0.00619	0.00717	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—bone cancer	0.006	0.00696	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—bone cancer	0.0059	0.00684	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—bone cancer	0.00588	0.00682	CcSEcCtD
Dihydroxyaluminium—Polyuria—Methotrexate—bone cancer	0.0058	0.00672	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—bone cancer	0.00555	0.00644	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—bone cancer	0.00553	0.00641	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—bone cancer	0.00551	0.00638	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—bone cancer	0.00537	0.00623	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Cisplatin—bone cancer	0.00527	0.00611	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—bone cancer	0.00512	0.00593	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—bone cancer	0.00509	0.00591	CcSEcCtD
Dihydroxyaluminium—Convulsion—Cisplatin—bone cancer	0.00484	0.00561	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—bone cancer	0.00478	0.00555	CcSEcCtD
Dihydroxyaluminium—Oedema—Cisplatin—bone cancer	0.00456	0.00529	CcSEcCtD
Dihydroxyaluminium—Infection—Cisplatin—bone cancer	0.00453	0.00525	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Cisplatin—bone cancer	0.00445	0.00516	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—bone cancer	0.00443	0.00514	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—bone cancer	0.00443	0.00513	CcSEcCtD
Dihydroxyaluminium—Hypotension—Cisplatin—bone cancer	0.00426	0.00494	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—bone cancer	0.0041	0.00475	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—bone cancer	0.00401	0.00465	CcSEcCtD
Dihydroxyaluminium—Pain—Cisplatin—bone cancer	0.0039	0.00452	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—bone cancer	0.00371	0.0043	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Cisplatin—bone cancer	0.00361	0.00418	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—bone cancer	0.00339	0.00394	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cisplatin—bone cancer	0.00336	0.0039	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—bone cancer	0.00331	0.00383	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—bone cancer	0.00318	0.00368	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—bone cancer	0.00316	0.00367	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cisplatin—bone cancer	0.00312	0.00362	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—bone cancer	0.00306	0.00355	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—bone cancer	0.00297	0.00344	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—bone cancer	0.00296	0.00343	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—bone cancer	0.00294	0.00341	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cisplatin—bone cancer	0.0029	0.00336	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—bone cancer	0.00289	0.00335	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—bone cancer	0.00278	0.00322	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—bone cancer	0.00276	0.00319	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—bone cancer	0.00274	0.00317	CcSEcCtD
Dihydroxyaluminium—Nausea—Cisplatin—bone cancer	0.00271	0.00314	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—bone cancer	0.0027	0.00314	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—bone cancer	0.00266	0.00308	CcSEcCtD
Dihydroxyaluminium—Vertigo—Epirubicin—bone cancer	0.00258	0.00299	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—bone cancer	0.00257	0.00298	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—bone cancer	0.0025	0.0029	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—bone cancer	0.00249	0.00288	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—bone cancer	0.00249	0.00288	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—bone cancer	0.00239	0.00277	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—bone cancer	0.00234	0.00272	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—bone cancer	0.00234	0.00271	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—bone cancer	0.00233	0.0027	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—bone cancer	0.0023	0.00267	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—bone cancer	0.00229	0.00265	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—bone cancer	0.00219	0.00254	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—bone cancer	0.00217	0.00251	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—bone cancer	0.00215	0.0025	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—bone cancer	0.00214	0.00248	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—bone cancer	0.00212	0.00245	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—bone cancer	0.00203	0.00235	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—bone cancer	0.002	0.00232	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—bone cancer	0.00199	0.00231	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—bone cancer	0.00198	0.00229	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—bone cancer	0.00186	0.00216	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—bone cancer	0.00185	0.00215	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—bone cancer	0.00185	0.00215	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—bone cancer	0.00184	0.00214	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—bone cancer	0.00173	0.002	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—bone cancer	0.00172	0.002	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—bone cancer	0.00171	0.00199	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—bone cancer	0.00171	0.00199	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—bone cancer	0.00166	0.00192	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—bone cancer	0.0016	0.00186	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—bone cancer	0.0016	0.00185	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—bone cancer	0.00159	0.00185	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—bone cancer	0.00155	0.0018	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—bone cancer	0.00149	0.00173	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—bone cancer	0.00149	0.00172	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—bone cancer	0.00148	0.00172	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—bone cancer	0.00143	0.00166	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—bone cancer	0.00139	0.00161	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—bone cancer	0.00138	0.0016	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—bone cancer	0.00129	0.00149	CcSEcCtD
